SoC therapy

DRUG4 trials

Sponsors

University of Campania Luigi Vanvitelli, Alexion Pharmaceuticals, Inc., University of Rome Tor Vergata, Shenyang Northern Hospital

Conditions

Clonal Hematopoiesis of Indeterminate PotentialColchicineCoronary Atherosclerosis ManagementCovid19Diabetic NephropathyWilson Disease

Phase 2

Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients

CompletedNCT04475120

University of Rome Tor VergataCovid19

Start: 2020-04-15End: 2020-07-02Updated: 2021-05-14

Phase 3

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

TerminatedNCT03403205

Alexion Pharmaceuticals, Inc.Wilson Disease

Start: 2018-02-22End: 2023-06-30Updated: 2024-06-17

Phase 4

Nephropathy In Type 2 Diabetes and Cardio-renal Events

CompletedNCT00535925

University of Campania Luigi VanvitelliDiabetic Nephropathy

Start: 2005-10-31End: 2019-05-31Updated: 2020-08-03

Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis

RecruitingNCT07362966

Shenyang Northern HospitalClonal Hematopoiesis of Indeterminate Potential, Colchicine, Coronary Atherosclerosis Management

Start: 2026-06-08End: 2027-12-01Target: 120Updated: 2026-06-30

Related Papers

The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial.

2022-11-0761 citations

Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease

Cardiovascular Diabetology2021-07-16126 citations

Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up study.

2016-10-1311 citations